<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218370</url>
  </required_header>
  <id_info>
    <org_study_id>LIBERATED</org_study_id>
    <secondary_id>R01DK122797</secondary_id>
    <nct_id>NCT04218370</nct_id>
  </id_info>
  <brief_title>Liberation From Acute Dialysis</brief_title>
  <acronym>LIBERATE-D</acronym>
  <official_title>LIBERation From AcuTE Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the LIBERATE-D clinical trial is to improve outcomes for patients recovering from&#xD;
      dialysis-requiring acute kidney injury (AKI-D). The impact of a conservative dialysis&#xD;
      strategy compared to standard clinical practice of thrice-weekly dialysis will be examined to&#xD;
      help generate knowledge for how to guide delivery of dialysis to facilitate renal recovery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dialysis-requiring acute kidney injury (AKI-D) is a devastating complication among&#xD;
      hospitalized patients for which there are no treatments other than supportive care. Recovery&#xD;
      of sufficient renal function to stop dialysis is an unequivocally important clinical and&#xD;
      patient-oriented outcome. Shortening dialysis duration and increasing the number of AKI-D&#xD;
      patients who recover would have a major clinical, public health and cost-saving impact.&#xD;
      However, there is currently no evidence to guide the delivery of dialysis to facilitate&#xD;
      recovery. The investigators hypothesize that in patients who have AKI-D and who are&#xD;
      hemodynamically stable, a conservative dialysis strategy--in which hemodialysis is not&#xD;
      continued unless specific metabolic or clinical indications for renal replacement therapy&#xD;
      (RRT) are present--will improve the likelihood of renal recovery compared with the current&#xD;
      standard clinical practice of thrice-weekly intermittent dialysis. The investigators have&#xD;
      conducted a pilot clinical trial to demonstrate the feasibility of this approach. The&#xD;
      investigators propose here a 2-center randomized controlled trial to test a conservative&#xD;
      dialysis strategy in a larger AKI-D population (N = 220).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with renal recovery at hospital discharge</measure>
    <time_frame>Up to 14 days after hospital discharge (to allow for ascertainment of outcome at hospital discharge, which requires a period of sustained dialysis independence)</time_frame>
    <description>Alive and off dialysis at the time of discharge, with sustained independence from dialysis for 14 days. This outcome does not require that all 14 days of sustained independence occur in-hospital.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of dialysis sessions/week</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of dialysis sessions prescribed in each treatment arm, expressed per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis-free days to study day 28</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The number of days that a patient did not need dialysis to study day 28. A patient can only accrue dialysis-free days after the final dialysis session that commences the monitoring period for renal recovery. Subjects who die before study day 28 will be considered to have zero dialysis-free days.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Renal recovery at day 28</measure>
    <time_frame>Up to 42 days (to allow for ascertainment of outcome at day 28, which requires a period of sustained dialysis independence)</time_frame>
    <description>Alive and off dialysis at day 28, with sustained independence from dialysis for 14 days.</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal recovery</measure>
    <time_frame>Up to 104 days (to allow for ascertainment of outcome at day 28, which requires a period of sustained dialysis independence)</time_frame>
    <description>Alive and off dialysis at day 90, with sustained independence from dialysis for 14 days.</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause in-hospital mortality</measure>
    <time_frame>Up to date of death from any cause, assessed up to 12 months</time_frame>
    <description>Vital status at the time of hospital discharge</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause day 28 mortality</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Vital status at day 28 after study enrollment</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause day 90 mortality</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Vital status at day 90 after study enrollment</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Up to date of hospital discharge or death from any cause, whichever comes first, assessed up to 12 months</time_frame>
    <description>Duration of hospital stay after study enrollment</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to renal recovery</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Days after study enrollment before renal recovery occurs</description>
  </other_outcome>
  <other_outcome>
    <measure>Pre-specified adverse events</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Adverse events that might be related to the dialysis intervention, including emergent dialysis sessions, intradialytic hypotension and post-dialysis hypotension</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Kidney; Disease, Acute</condition>
  <condition>Dialysis Related Complication</condition>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thrice-weekly intermittent dialysis until pre-specified criteria for recovery are met</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conservative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conservative dialysis strategy--dialysis prescribed only when specific metabolic or clinical indications are met. These indications are: blood urea nitrogen &gt;112 mg/dL (40 mmol/L; blood potassium concentration &gt;6 mmol/L; blood potassium concentration &gt;5.5 mmol/L despite medical treatment; arterial blood gas pH &lt;7.15, or in the absence of an available blood gas, serum bicarbonate &lt;12 mmol/L, acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate &gt;5 L/min or equivalent via face mask/tracheostomy mask to maintain SpO2 &gt;95% or requiring FiO2 &gt;50% in patients with tracheostomy already on invasive or non-invasive mechanical ventilation and despite diuretic therapy; clinician judgement</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dialysis</intervention_name>
    <description>Dialysis treatment, either in the form of hemodialysis or continuous renal replacement therapy (if patient develops hemodynamic instability)</description>
    <arm_group_label>Conservative</arm_group_label>
    <arm_group_label>Conventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â‰¥ 18 years of age&#xD;
&#xD;
          -  Inpatient with AKI-D (intermittent hemodialysis or continuous renal replacement&#xD;
             therapy received on at least one calendar day) at least partially due t acute tubular&#xD;
             necrosis per the clinical nephrology team&#xD;
&#xD;
          -  Hemodynamic stability: not requiring vasopressor support and with planned intermittent&#xD;
             dialysis&#xD;
&#xD;
          -  Baseline estimated glomerular filtration rate (eGFR) â‰¥ 15 mL/min/1.73 m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nontraditional indication for dialysis (end-stage liver disease awaiting&#xD;
             transplantation, fulminant hepatic failure, intoxication)&#xD;
&#xD;
          -  Complete nephrectomy as cause of AKI-D&#xD;
&#xD;
          -  Kidney transplant during index hospitalization&#xD;
&#xD;
          -  Dialysis &gt; 3 months&#xD;
&#xD;
          -  Decompensated heart failure requiring left ventricular assist device or continuous&#xD;
             inotropic support&#xD;
&#xD;
          -  Mechanical ventilation via endotracheal tube&#xD;
&#xD;
          -  Hypoxemia requiring significant oxygen support: &gt;5 liters/min via nasal cannula or&#xD;
             equivalent via face mask/tracheostomy mask to maintain oxygen saturation &gt; 95%, or&#xD;
             requiring fraction of inspired oxygen &gt;50% in patients with tracheostomy requiring&#xD;
             invasive or non-invasive ventilation&#xD;
&#xD;
          -  Unable to consent and no surrogate decisionmaker available&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Prisoner&#xD;
&#xD;
          -  Clinical team declines to allow study participation&#xD;
&#xD;
          -  Anticipated discharge or transfer from study hospital within 48 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Liu, MD, PhD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chi-yuan Hsu, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen Liu, MD, PhD, MAS</last_name>
    <phone>4155027998</phone>
    <email>kathleen.liu@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chi-yuan Hsu, MD, MSc</last_name>
    <phone>4153532379</phone>
    <email>chi-yuan.hsu@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Califonia, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Liu, MD, PhD, MAS</last_name>
      <phone>415-502-7998</phone>
      <email>kathleen.liu@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chi-yuan Hsu, MD, MSc</last_name>
      <phone>415-353-2379</phone>
      <email>chi-yuan.hsu@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathleen Liu, MD, PhD, MAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chi-yuan Hsu, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Siew, MD</last_name>
      <phone>615-343-1279</phone>
      <email>edward.siew@vumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

